Success stories

Novo Nordisk is a global pharmaceutical company with 90-year history of innovations and leadership in diabetes treatment. More than 28 mln persons in 180 countries use Novo Nordisk medicines for diabetes therapy on a daily basis. These are every second patient worldwide. The Company also has leading positions in such areas as hemostasis control, therapy with somatotropic hormone, hormonal replacement therapy for women and for obesity treatment.

Total volume of investments amounted to more than RUR 8 bln. Novo Nordisk headquarters are located in Denmark; there are more than 42,000 employees working at 77 subsidiaries of the Company, and its products are supplied to more than 165 countries.

“The construction of the new plant in Kaluga shall be viewed as a clear demonstration of Novo Nordisk long-term commitment to provide support to Russian people suffering diabetes. According to available research data some ten million people in Russia suffer from this disease. Our investments in the Russian plant ensure availability of high quality next generation insulin to Russian patients who have to take insulin every single day.”

Lars Rebien Sorensen, Novo Nordisk CEO

Novo Nordisk plant is the first in Russia and the only one greenfield project to produce comprehensive portfolio of modern insulins (Levemir®, NovoRapid® and NovoMix® 30). The plant produces the insulin solution from own original substance, it fills and packs insulins in cartridges as well as in pens. The most advanced technologies are used in the project as far as it concerns environmental safety and energy efficiency.

Construction of the plant in Kaluga fully complies with the Strategy of Russian Pharmaceutical Industry Development for 2020 perspective; it strengthens drug safety of the country, makes substantial contribution to the development of pharmaceutical industry, and promotes high technologies transfer and higher level of diabetes treatment in Russia.

The most advanced energy efficient and safe technologies are use at the Company’s Kaluga plant. All production processes comply with standards of Good Manufacturing Practices (GMP).